*ST河化(000953.SZ):南鬆醫藥已向南鬆凱博增資5000萬元
格隆匯 11 月 10日丨*ST河化(000953.SZ)公佈,公司第九屆董事會第十一次會議審議通過了《關於控股子公司對其下屬子公司增資的議案》,同意公司控股子公司重慶南鬆醫藥科技有限公司(“南鬆醫藥”)以自有資金對其全資子公司重慶南鬆凱博生物製藥有限公司(“南鬆凱博”)增資5000萬元人民幣,全部由南鬆醫藥認繳,即南鬆凱博註冊資本增加至12000萬元人民幣。
截至目前,南鬆醫藥已按照相關規定向南鬆凱博增資5000萬元人民幣,南鬆凱博已完成工商變更登記等相關手續,註冊資本變更為12000萬元人民幣,此次增資已完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.